Company Description
Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases.
The company’s EEV platform develops products based on oligonucleotide, enzyme, and antibody-conjugated EEV peptides.
Its therapeutic candidates, which include ENTR-601-44 that is in Phase 1 clinical trial for the treatment of Duchenne muscular dystrophy; and VX-670, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.
The company also offers ENTR-601-45, ENTR-601-50, and ENTR-601-51, which are in preclinical trial, for the treatment of Duchenne muscular dystrophy; and PTI-501, an intracellular thymidine phosphorylase enzyme replacement therapy for the treatment of mitochondrial neurogastrointestinal encephalomyopathy.
It has strategic collaboration and license agreements with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize VX-670; and Pierrepont Therapeutics, Inc. to advance the development of PTI-501.
The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017.
Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
| Country | United States |
| Founded | 2016 |
| IPO Date | Oct 29, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 183 |
| CEO | Dipal Doshi |
Contact Details
Address: One Design Center Place, Suite 17- 500 Boston, Massachusetts 02210 United States | |
| Phone | 857 520 9158 |
| Website | entradatx.com |
Stock Details
| Ticker Symbol | TRDA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 0001689375 |
| CUSIP Number | 29384C108 |
| ISIN Number | US29384C1080 |
| Employer ID | 81-3983399 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dipal Doshi | Chief Executive Officer and Director |
| Nathan J. Dowden | President and Chief Operating Officer |
| Dr. Natarajan Sethuraman Ph.D. | President of Research and Development |
| Leo Qian Ph.D. | Co-Founder and Vice President of Discovery Research |
| Kory James Wentworth CPA | Chief Financial Officer and Treasurer |
| Dr. Jared Cohen J.D., Ph.D. | General Counsel |
| Kerry Robert M.S. | Senior Vice President of People |
| Karla MacDonald | Chief Corporate Affairs Officer |
| Kevin Healy Ph.D. | Senior Vice President of Regulatory Affairs |
| Murali Mallem | Vice President and Head of CMC |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 25, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 24, 2025 | 8-K | Current Report |
| Mar 17, 2025 | 144 | Filing |
| Feb 27, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 27, 2025 | 10-K | Annual Report |
| Feb 27, 2025 | 8-K | Current Report |
| Feb 24, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 14, 2025 | SCHEDULE 13G | Filing |
| Feb 4, 2025 | SCHEDULE 13G | Filing |